Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
As at 2023-12-31 |
2023-01-01 to 2023-12-31 |
As at 2022-12-31 |
|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | |||
| Name of reporting entity or other means of identification | — |
Egetis Therapeutics AB (publ
|
— |
| Legal form of entity | — |
AB (publ)
|
— |
| Country of incorporation | — |
Sverige
|
— |
| Address of entity's registered office | — |
Klara Norra Kyrkogata 26
|
— |
| Description of nature of entity's operations and principal activities | — |
Egetis är ett innovativt och integrerat läkemedels-
|
— |
| Statement of IFRS compliance [text block] | — |
Grund för rapporternas upprättande
|
— |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | |||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | |||
| Current inventories |
7,000,000
SEK
|
— |
6,000,000
SEK
|
| Current trade receivables |
282,000,000
SEK
|
— |
38,000,000
SEK
|
| Current trade payables |
287,000,000
SEK
|
— |
200,000,000
SEK
|
| Disclosure of material accounting policy information [text block] | — |
NOT
|
— |